

Effect of Glucagon-Like Peptide-1 Deprescription Following Nutrition Therapy via Telemedicine on Glycemia and Body Weight among People with Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study

Amy L. McKenzie, PhD†; Shaminie J. Athinarayanan, PhD†

Virta Health, Denver, CO, USA

† These authors contributed equally

ABSTRACT

Introduction

Recent clinical trials demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1) elicit substantial reductions in glycemia and body weight in people with type 2 diabetes and obesity but must be continued indefinitely to maintain clinical improvements. Given the high cost and poor real-world persistence of GLP-1, an effective maintenance therapy that enables deprescription and sustained clinical improvements would be valuable. Thus, the purpose of this real-world study was to assess the effect of GLP-1 deprescription on glycemia and body weight following co-therapy with carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model among people with type 2 diabetes and excess body weight.

Research Design and Methods

A retrospective, propensity score matched cohort study among patients with type 2 diabetes at a nationwide telemedicine clinic was conducted using medical record data. Patients in whom GLP-1 were deprescribed (DeRx; n=154) were matched 1:1 with patients in whom GLP-1 were continued (Rx) or never prescribed (NonGLP). Longitudinal and between matched cohort differences in HbA1c and weight were assessed at enrollment, deprescription/index date, and 6 and 12 months (m) post-deprescription/index date using a linear mixed effects model.

Results

Hemoglobin A1c and body weight measured 6 and 12 months following deprescription/index date did not significantly differ between cohorts and improved at deprescription/index date and at follow up intervals compared to enrollment. HbA1c rose 6- and 12m post-deprescription/index in both DeRx and Rx and at 12m in NonGLP ($p<0.001$) but most patients maintained A1c $<6.5\%$. No regression in body weight was observed with $>70\%$ maintaining $\geq 5\%$ body weight loss 12m post-deprescription/index date.

Conclusions

These results demonstrate that CRNT in a continuous remote care model provides an effective GLP-1 step-off and maintenance therapy, allowing patients to discontinue GLP-1 while maintaining body weight loss and glycemia below therapeutic targets.

KEY MESSAGES

What is already known on this topic

Glucagon-like peptide-1 receptor agonists (GLP-1) have demonstrated in clinical trials significant reductions in glycemia and body weight among patients with type 2 diabetes and obesity with rapid regression of clinical improvements upon discontinuation of the medication even with persistent caloric restriction and exercise counseling, suggesting the drug must be continued indefinitely.

Cost and poor persistence of the GLP-1 therapy pose real-world challenges to maintaining improved health outcomes long-term, so therapies that enable deprescription and maintenance of clinical improvements are needed.

What this study adds

This study assessed the potential for utilization of carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model as a GLP-1 step-off and subsequent maintenance therapy.

HbA1c and body weight up to 12 months following GLP-1 deprescription did not differ from matched cohorts in whom GLP-1 were continued or never utilized in this real-world study.

How this study might affect research, practice or policy

This study informs clinical practice, showing that the CRNT supported by continuous remote care provides an effective GLP-1 step-off therapy, enabling maintenance of improved glycemia and weight loss following GLP-1 deprescription and mitigating the need for lifetime, continuous use of the pharmaceutical.

INTRODUCTION

About one in seven adults in the United States lives with type 2 diabetes,[1] and 78% also live with excess weight or obesity.[2] Prevalence of type 2 diabetes, excess weight, and obesity continue to grow[3,4] alongside the cost of healthcare for these conditions,[5,6] particularly through introduction of high cost medications associated with significant weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1).[7,8]

Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in type 2 diabetes[9,10] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without type 2 diabetes.[11,12] However, clinical trial evidence to date demonstrates the high efficacy and high cost drugs must be continued indefinitely to sustain improved clinical outcomes.[13,14]

Lifestyle intervention, as the cornerstone of type 2 diabetes and obesity care, may serve as an effective combination and sequential therapy to pharmaceuticals to enable eventual deprescription – particularly among interventions demonstrated to elicit significant weight loss, regression of prediabetes to normoglycemia, and remission of type 2 diabetes, such as carbohydrate restricted nutrition therapy.[15,16] Using real-world data, we assessed the impact of GLP-1 deprescription on glycemia and body weight among people with type 2 diabetes and excess weight or obesity compared to matched cohorts of patients who continued GLP-1 therapy and never utilized GLP-1 therapy to evaluate the feasibility of and potential for utilization of carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model as a GLP-1 step-off therapy.

RESEARCH DESIGN AND METHODS

Study population and design

This retrospective real-world analysis utilized de-identified data obtained from medical records among patients of Virta Health, a nationwide telemedicine clinic serving people with type 2 diabetes, prediabetes, and obesity. Patients in the clinic are advised in carbohydrate restricted nutrition therapy, including a well-formulated and medically-supervised ketogenic diet, through use of a health application (app) where patients connect with their care team consisting of a medical provider and health coach and have continuous access to biomarker logging, educational resources, and peer support.

We identified patients with a diagnosis of type 2 diabetes who were prescribed a GLP-1 upon enrollment in the clinic whose GLP-1 was subsequently deprescribed following improved glycemia to $A1c < 6.5\%$ within 3-9 months of beginning CRNT (GLP-1 deprescription cohort). To assess A1c and weight changes after deprescription in context with alternate therapeutic strategies, two matched cohorts were identified: 1) patients who were prescribed GLP-1 at enrollment and remained on GLP-1 therapy (continued GLP-1 therapy cohort) and 2) patients who were never prescribed a GLP-1 (non-GLP-1 therapy cohort).

Outcomes and study measures

The primary aim was to determine if HbA1c or body weight differed among the GLP-1 deprescription, continued GLP-1 therapy, and non-GLP-1 therapy cohorts in the year following deprescription or index date. In addition to HbA1c, body weight, and diabetes medication data, demographics and app data, including gender, age, race and ethnicity, and daily fingerstick blood beta-hydroxybutyrate (BHB; a biomarker of adherence to the CRNT) were obtained for this analysis.

Statistical method

To adjust for confounders and minimize bias, propensity score matching was used to match each patient in the GLP-1 deprescription cohort (reference cohort) 1:1 with a patient in the other two therapeutic cohorts. The reference cohort was matched using propensity scores estimated from a multivariate regression model and the nearest neighbor method without any replacement. For matching, enrollment and index date covariates included age, gender, race and ethnicity, HbA1c, body mass index (BMI), number of diabetes medications, and distribution of follow-up HbA1c and weight data availability and the GLP-1 drug prescribed at enrollment. To assess balance between the cohorts after matching, baseline covariates were assessed using ANOVA or Chi-Square test in all three cohorts and standardized differences were assessed between cohorts.

Longitudinal and between matched cohort differences in HbA1c and weight were assessed at enrollment, deprescription or index date, and 6 and 12 months post-deprescription or index date using linear mixed effects models. Additionally, we repeated the analyses in two medication subgroups with sufficient sample size (semaglutide and dulaglutide).

We assessed longitudinal changes in BHB in the matched cohorts using two different methods. First, the daily BHB measurements were compiled as count data where percentage days of logging BHB $\geq 0.3\text{mM}$ (indicative of carbohydrate restriction and low levels of nutritional ketosis) were calculated for the four main time intervals: enrollment to deprescription or index date, deprescription or index date ± 3 months, and 6 ± 3 and 12 ± 3 months post-deprescription or index date. We then used generalized estimating equations (GEE) with an unstructured correlation matrix, logarithmic link, and Poisson distribution to assess longitudinal changes and rate of change in frequency of BHB $\geq 0.3\text{mM}$ between the three matched cohorts. Second, mean BHB was calculated for the four main time intervals and a linear mixed effect model was used to assess longitudinal changes in mean BHB and the rate of mean BHB changes between the three matched cohorts.

All analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria) version 4.2.2 (2022-10-31) and IBM SPSS statistics (version 29.0.1.0). Two-sided *p* values less than 0.05 were considered statistically significant.

RESULTS

Patient characteristics of the propensity-score matched cohorts are described in Table 1. No significant differences were observed between matched cohorts, and cohorts were balanced according to absolute standardized differences. Within the deprescription cohort, the medication most frequently prescribed at enrollment in the clinic was dulaglutide (43.5%), followed by

semaglutide (29.2%), liraglutide (17.5%), and exenatide (7.1%). The mean duration of care in all three cohorts was at least 18 months.

Table 1. Baseline characteristics of the matched cohorts

	GLP-1 Deprescription Cohort (n=154)	Continued GLP-1 Therapy Cohort (n=154)	Non-GLP-1 Therapy Cohort (n=154)
Age, mean (SD), years	55.9 (8.7)	55.3 (8.4)	55.5 (9.2)
Gender, n (%)			
Female	77 (50.0)	90 (58.4)	84 (54.5)
Male	77 (50.0)	64 (41.6)	70 (45.5)
Race and Ethnicity (n,%)			
Non-Hispanic White	100 (64.9)	108 (70.1)	105 (68.2)
Non-Hispanic Black or African American	9 (5.8)	19 (12.3)	13 (8.4)
Hispanic	29 (18.8)	19 (12.3)	19 (12.3)
Non-Hispanic American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, or Multiple Races	7 (4.5)	8 (5.2)	13 (8.4)
Enrollment BMI mean (SD), kg/m²	35.7 (6.9)	36.5 (7.2)	36.2 (7.8)
Enrollment HbA1c mean (SD), %	7.3 (1.2)	7.4 (1.4)	7.3 (1.0)

Hemoglobin A1c and body weight measured 6 and 12 months following deprescription or index date did not significantly differ between cohorts (Figure 1). In all cohorts, HbA1c and body weight improved significantly at time of deprescription or index date and at follow up intervals compared to enrollment. In both the deprescription and continued therapy cohorts, HbA1c at 6 and 12 month follow up rose relative to deprescription or index date ($p < 0.001$); in the non-GLP-1 therapy cohort, HbA1c rose at 12 months post-index date ($p < 0.001$). However, HbA1c for most individuals remained below 6.5% up to 12 months following deprescription or index date in all cohorts (deprescription: 64.8%; continued: 64.1%; non-GLP-1 therapy: 67.6%) including 20.4%, 20.3%, and 20.6% of the deprescription, continued, and non-GLP-1 therapy cohorts who maintained normoglycemia ($\text{HbA1c} < 5.7\%$) 12 months following deprescription or index date. No significant regression of body weight following deprescription or index date was observed in any cohort. More than 70% of patients in each of the matched cohorts maintained at least 5% body weight loss 12 months following deprescription or index date (Figure 2). Subgroup analyses of semaglutide and dulaglutide were consistent with the full cohort and HbA1c and body weight changes by medication are described in Figure 3.

Frequency of achieving $\text{BHB} \geq 0.3\text{mM}$ via CRNT declined more rapidly among the continued GLP-1 therapy cohort compared to the other cohorts ($p = 0.037$), and mean BHB of the continued

GLP-1 therapy cohort was lower compared to the other cohorts at all time intervals ($p < 0.05$; Figure 4).

CONCLUSIONS

Results of this real-world analysis show no differences in glycemia or body weight up to 12 months following deprescription of GLP-1 in people with type 2 diabetes compared to matched cohorts in whom GLP-1 therapy was continued or no GLP-1 therapy was utilized, suggesting that carbohydrate restricted nutrition therapy supported via a continuous remote care model may be effectively utilized to step off GLP-1 therapy and used as a maintenance therapy. More frequent maintenance of nutritional ketosis achieved through CRNT was observed in the deprescription and non-GLP1 therapy cohorts during the deprescription or index time interval compared to the continued GLP1 therapy cohort, providing a potential indicator for likelihood of maintaining HbA1c and body weight following GLP-1 deprescription and tool for guiding patient care and assisting with clinical decision making regarding deprescription.

The STEP 1 Trial Extension showed rapid regression in glycemia and body weight following withdrawal of semaglutide administered in conjunction with a physical activity and caloric restriction lifestyle intervention.[13] One year after therapy withdrawal, participants regained 64% of weight lost and 80% of the decline in HbA1c that had been achieved. Although the STEP 1 Extension did not include people with type 2 diabetes, it is reasonable to expect similar regression upon withdrawal of the drug among those with type 2 diabetes. Results from the present real-world analysis contrast prior research, showing less regression of outcomes — only 15% of the body weight lost and 36% of the HbA1c decline achieved in combination with CRNT prior to GLP-1 deprescription in the year following discontinuation of the medication, despite being in a group with more progressive insulin resistance. Specifically among those deprescribed semaglutide, there was no regression in body weight one year following discontinuation and a 40% regression in the HbA1c decline. Given these patients were prescribed GLP-1 therapy prior to initiating care at this clinic, it is reasonable to expect GLP-1 therapy resulted in significant HbA1c and body weight reductions prior to those achieved by adding CRNT and continuous remote care, suggesting the overall regression in HbA1c and body weight in the context of GLP-1 deprescription and continued CRNT may be even less than what can be observed in these data.

The STEP 4 trial assessed withdrawal of the medication, but not the lifestyle intervention, and showed regain of about half of the weight lost during combination therapy over the next 11 months. The lifestyle intervention studied in the STEP 1 extension and STEP 4 trial focused on caloric restriction and exercise with monthly in-person or telephone counseling, while the lifestyle intervention in the present real-world study focuses primarily on CRNT with continuous remote support, suggesting that the type of nutrition therapy and degree of support utilized as a combination and sequential therapy may play a key role in the ability to maintain weight loss following discontinuation of the GLP-1.

One potential reason dietary carbohydrate restriction, and nutritional ketosis in particular, may provide an advantage for weight loss maintenance following GLP-1 deprescription is through reduced hunger and appetite — an effect shared by both the drug and the nutrition therapy. Participants in a clinical trial evaluating the effects of the CRNT utilized in the present study reported reduced perceptions of hunger after ten weeks of therapy concurrent with mean blood

BHB of 0.6mM,[17] and blood BHB concentrations are associated with lower concentrations of the hunger hormone ghrelin and higher concentrations of satiety hormones glucagon-like peptide-1 and cholecystokinin.[18] Given the differences in BHB concentrations and frequency with which nutritional ketosis was maintained between the cohorts, blood BHB concentrations also appear to support clinical decision making regarding GLP-1 deprescription in addition to supporting patients in their daily nutrition choices and may be a useful indicator of likelihood of success in maintaining clinical improvements upon deprescription.

Longitudinal changes in HbA1c did not differ between deprescription and continued therapy cohorts, though the frequency of achieving BHB \geq 0.3 mM with CRNT and mean BHB was higher within the deprescription cohort. Carbohydrate restriction results in less glycemic variability[19], particularly post-meal – an effect similar to that which is achieved with GLP-1 therapy through delayed gastric emptying.[20,21] Further, reduced carbohydrate intake may to some degree replace the need for glucose-dependent insulin secretion with GLP-1 therapy.

Another noteworthy observation from this study was that patients on GLP-1 therapy at enrollment achieved an additional 13% weight loss and 1.6% reduction in HbA1c upon initiating CRNT in combination with GLP-1 therapy. Further improvement in glycemia and weight elicited with this combination therapy exceeds effects observed in other real-world studies among those who switched to injectable semaglutide from less potent GLP-1.[22,23] Further, the weight loss achieved with carbohydrate restriction and GLP-1 combination therapy was on par or greater than weight loss observed in STEP 2 among people with type 2 diabetes treated with 2.4 mg and 1.0 mg semaglutide[10], suggesting there may be benefit to pairing GLP-1 with carbohydrate restricted nutrition therapy to achieve greater weight loss when clinically indicated or to enable greater weight loss when higher doses are poorly tolerated, prior to stepping off GLP-1 therapy.

Additionally, cost and side effects are important considerations in GLP-1 therapy, and may contribute to the rates of uptake, adherence, and persistence observed throughout the United States today. For example, real world persistence of GLP-1 therapy at one year is approximately 50%.[24] This suggests multiple therapeutic options must be accessible to enable the desired clinical outcomes for individual patients with unique preferences and circumstances. The achievement of significant weight loss among those who never utilized GLP-1 therapy in this analysis suggests CRNT with continuous remote care may provide a reasonable, effective, and lower cost alternative for those who contend with access, financial, or tolerability barriers or prefer nonpharmacological therapy.

Strengths of this analysis include its use of real-world data from a nationwide clinic, broadening the applicability of its findings, and that it is, to the best of the authors' knowledge, the first study to assess glycemia and weight outcomes following withdrawal of GLP-1 in type 2 diabetes and under free-living, real-world conditions. Use of real-world data also has limitations given its retrospective and observational nature, even though differences between cohorts were reduced using matched cohort analysis. Duration of GLP-1 use prior to enrollment in the clinic and adherence could not be accounted for. Application of these findings are limited to the medications utilized by the patient population included in this analysis. Future research should

evaluate the effect of GLP-1 deprescription including medications which have recently come to market as indicated for type 2 diabetes and for excess weight or obesity without type 2 diabetes.

In conclusion, results of this real-world analysis demonstrate that GLP-1 can be deprescribed without negative effects on glycemia and body weight following co-therapy with carbohydrate restricted nutrition therapy supported in a continuous remote care model compared to matched cohorts in which GLP-1 therapy was continued or not utilized. These real-world data contrast clinical trial evidence in which rapid weight regain was observed following discontinuation of GLP-1 therapy even when traditional caloric restriction and physical activity counseling persisted and suggest that carbohydrate restricted nutrition therapy and continuous care may provide an appropriate glycemia and body weight maintenance therapy, mitigating the need for lifelong, continued GLP-1 therapy.

FIGURE LEGENDS

Figure 1 Comparison of HbA1c and body weight

Longitudinal and between group change in estimated mean (A) hemoglobin A1c (HbA1c, %) and (B) body weight (kg) from enrollment to 12 months post deprescription or index date in GLP-1 deprescription, continued GLP-1 therapy, and non-GLP-1 therapy cohorts.

Figure 2 Proportion of patients maintaining weight loss targets at 12-months post-deprescription or index date by cohort

Figure 3 Comparison of change in HbA1c and body weight by GLP-1 medication

Longitudinal change in estimated means from enrollment through 12 months post deprescription or index date:

- A. HbA1c (%) in GLP-1 deprescription cohort by types of GLP-1; all GLP-1, dulaglutide, exenatide, liraglutide and semaglutide
- B. HbA1c (%) in subcohort analysis in those initially prescribed or continued prescribed semaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- C. HbA1c (%) in subcohort analysis in those initially prescribed or continued prescribed dulaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- D. Weight (kg) in GLP-1 deprescription cohort by types of GLP-1; all GLP-1, dulaglutide, exenatide, liraglutide and semaglutide
- E. Weight (kg) in subcohort analysis in those initially prescribed or continued prescribed semaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- F. Weight (kg) in subcohort analysis in those initially prescribed or continued prescribed dulaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts

Figure 4 Comparison of nutritional ketosis parameters by cohort

Longitudinal change in estimated mean (A) percentage days of logging BHB ≥ 0.3 mM and (B) BHB (mM) from enrollment to 12 \pm 3 months post deprescription or index date in GLP-1 deprescription, continued GLP-1 therapy, and non-GLP-1 therapy cohorts

ACKNOWLEDGMENTS

The authors would like to thank Mitch Graves, Ed Jiang, and Pang Weirich for their assistance with data compilation and Caroline Roberts, Greeshma Shetty, and Jeff Stanley for sharing their clinical insight to inform this research.

COMPETING INTERESTS

Both authors are employed by and hold stock in Virta Health Corp.

FUNDING

None.

CONTRIBUTORS

AM and SA contributed to the concept, design, and planning of the study as well as interpretation of the study results. SA analyzed the data. AM drafted the manuscript and SA reviewed.

ETHICS APPROVAL

This study did not require IRB approval as it was a retrospective databased study in which subjects were properly de-identified to maintain confidentiality. No human subjects were at risk during this study.

DATA AVAILABILITY STATEMENT

Data may be obtained from a third party and are not publicly available.

REFERENCES

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2022 [Internet]. Available from: <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
2. Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. *Curr Med Res Opin.* 2016;32(7):1243–52.
3. Centers for Disease Control and Prevention. National and State Diabetes Trends [Internet]. Available from: <https://www.cdc.gov/diabetes/library/reports/reportcard/national-state-diabetes-trends.html>
4. National Center for Health Statistics. Table 26. Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States, selected years 1988–1994 through 2015–2018 [Internet]. (Health, United States, 2019). Available from: <https://www.cdc.gov/nchs/hus/data-finder.htm>
5. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. *Diabetes Care.* 2018;41(5):dci180007.
6. Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. *J Manag Care Spec Ph.* 2021;27(3):354–66.
7. Neilson LM, Munshi KD, Peasah SK, et al. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019. *Med Care.* 2021;59:789–94.
8. Heyward J, Christopher J, Sarkar S, Shin J, Kalyani RR, Alexander GC. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. *Diabetes Obes Metabolism.* 2021;23(8):1843–50.
9. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet.* 2021;398(10295):143–55.
10. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397:971–84.
11. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New Engl J Med.* 2022;387(3):205–16.
12. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New Engl J Med.* 2021;384(11):989-1002

13. Wilding JPH, Batterham RL, Davies M, , et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metabolism*. 2022;24(8):1553–64.
14. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. *JAMA*. 2021;325(14):1414–25.
15. McKenzie AL, Athinarayanan SJ, McCue JJ, et al. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. *Nutrients*. 2021;13(3):749.
16. Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. *Front Endocrinol*. 2019;10:348.
17. McKenzie AL, Hallberg SJ, Creighton BC, et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. *JMIR Diabetes*. 2017;2(1):e5.
18. Martins C, Nymo S, Truby H, Rehfeld JF, Hunter GR, Gower BA. Association Between Ketosis and Changes in Appetite Markers with Weight Loss Following a Very Low Energy Diet. *Obesity*. 2020;28(12):2331–8.
19. Tay J, Thompson CH, Luscombe Marsh ND, , et al. Effects of an energy restricted low carbohydrate, high unsaturated fat/low saturated fat diet versus a high carbohydrate, low fat diet in type 2 diabetes: A 2 year randomized clinical trial. *Diabetes Obes Metabolism*. 2018;20(4):858–71.
20. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones. *Diabetes Care*. 2013;36(5):1396–405.
21. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. *Regul Pept*. 2008;151:123–9.
22. Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. *Diabetes Ther*. 2021;12(3):879–96.
23. Crabtree TSJ, Adamson K, Reid H, et al. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide 1 receptor agonists. *Diabetes, Obes Metab*. 2022;24(7):1398–401.
24. Weiss T, Yang L, Carr RD, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. *BMJ Open Diabetes Res Care*. 2022;10(1):e002517.

Smartcite references below FOR SAFE KEEPING IN THE EVENT OF EDITS/CHANGES


1. Prevention C for DC and. National Diabetes Statistics Report 2022 [Internet]. Available from: <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
2. Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. *Curr Med Res Opin.* 2016;32(7):1243–52.
3. Prevention C for DC and. National and State Diabetes Trends [Internet]. Available from: <https://www.cdc.gov/diabetes/library/reports/reportcard/national-state-diabetes-trends.html>
4. Statistics NC for H. Table 26. Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States, selected years 1988–1994 through 2015–2018 [Internet]. (Health, United States, 2019). Available from: <https://www.cdc.gov/nchs/hus/data-finder.htm>
5. Association AD. Economic Costs of Diabetes in the U.S. in 2017. *Diabetes Care.* 2018;41(5):dci180007.
6. Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG, et al. Direct medical costs of obesity in the United States and the most populous states. *J Manag Care Spec Ph.* 2021;27(3):354–66.
7. Neilson LM, Munshi KD, Peasah SK, Huang Y, Swart ECS, Henderson R, et al. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019. *Med Care.* 2021;59:789–94.
8. Heyward J, Christopher J, Sarkar S, Shin J, Kalyani RR, Alexander GC. Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. *Diabetes Obes Metabolism.* 2021;23(8):1843–50.
9. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Landó LF, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet.* 2021;398(10295):143–55.
10. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397:971–84.

11. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New Engl J Med.* 2022;387(3):205–16.
12. Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New Engl J Med.* 2021;384(11):989–1002.
13. Wilding JPH, Batterham RL, Davies M, Gaal LFV, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metabolism.* 2022;24(8):1553–64.
14. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. *Jama.* 2021;325(14):1414–25.
15. McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, et al. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. *Nutrients.* 2021;13(3):749.
16. Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. *Front Endocrinol.* 2019;10:348.
17. McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. *Jmir Diabetes.* 2017;2(1):e5.
18. Martins C, Nymo S, Truby H, Rehfeld JF, Hunter GR, Gower BA. Association Between Ketosis and Changes in Appetite Markers with Weight Loss Following a Very Low Energy Diet. *Obesity.* 2020;28(12):2331–8.
19. Tay J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Noakes M, Buckley JD, et al. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. *Diabetes Obes Metabolism.* 2018;20(4):858–71.
20. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones. *Diabetes Care.* 2013;36(5):1396–405.
21. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. *Regul Pept.* 2008;151:123–9.


22. Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. *Diabetes Ther.* 2021;12(3):879–96.
23. Crabtree TSJ, Adamson K, Reid H, Barnes D, Sivappriyan S, Bickerton A, et al. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. *Diabetes, Obes Metab.* 2022;24(7):1398–401.
24. Weiss T, Yang L, Carr RD, Pal S, Sawhney B, Boggs R, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. *Bmj Open Diabetes Res Care.* 2022;10(1):e002517.

Figure 1.

A.



B.



GLP-1 Discontinuation Cohort Continued GLP-1 Therapy Cohort Non-GLP-1 Therapy Cohort

Figure 2.






Figure 3.

A.




D.




— All GLP-1 — Dulaglutide — Exenatide — Liraglutide — Semaglutide

B. Semaglutide




E. Semaglutide




—●— GLP-1 Deprescription Cohort —●— Continued GLP-1 Therapy Cohort

C. Dulaglutide




F. Dulaglutide




—●— GLP-1 Deprescription Cohort —●— Continued GLP-1 Therapy Cohort

Figure 4.

A.



B.



—●— GLP-1 Deprescription Cohort —●— Continued GLP-1 Therapy Cohort —●— Non-GLP-1 Therapy Cohort